The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Corticosteroid-induced clinical adverse events: frequency, risk factors and patient?s opinion
Open accessAbstract
BACKGROUND: More than 50 years after the introduction of corticosteroids, few studies have focused on corticosteroid-induced adverse events after long-term systemic therapy. OBJECTIVES: To assess the frequency, risk factors and patient's opinion regarding clinical adverse events occurring early during prednisone therapy. PATIENTS AND METHODS: We conducted a cohort study in two French centres. All consecutive patients starting long-term (> oir = 3 months), high dosage (> or = 20 mg day(-1)) prednisone therapy were enrolled. The main clinical adverse events attributable to corticosteroids were assessed after 3 months of therapy, by comparison with baseline status. The patient's opinion regarding the disability induced by these adverse events was recorded. Risk factors of frequently observed adverse effects were identified by using logistic regression. RESULTS: Eighty-eight patients were enrolled and 80 were monitored for at least 3 months (women 76%; mean age 59.1 +/- 18.7 years; giant cell arteritis 39%; mean baseline prednisone dosage 54 +/- 17 mg day(-1)). Lipodystrophy was the most frequent adverse event [63.0% (51.0-73.1)], was considered the most distressing by the patients and was most frequent in women and young patients. Neuropsychiatric disorders occurred in 42 patients [52.5% (41.0-63.8)], necessitating hospitalization in five cases. Skin disorders were noted by 37 patients [46.2% (35.0-57.7)] and were more frequent in women. Muscle cramp and proximal muscle weakness were reported by 32.5% (22.5-43.9) and 15% (8.0-24.7) of patients, respectively. Newly developed hypertension occurred in 8.7% (2.9-20.3) of patients. Lastly, 39% (19.7-61.4) of the premenopausal women reported menstrual disorders. CONCLUSIONS: Lipodystrophy and neuropsychiatric disorders are common adverse events of long-term prednisone therapy and are particularly distressing for the patients concerned. The impact of these adverse events on adherence to corticosteroid therapy is not known.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults
Grinspoon, S., & Carr, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041811 · Cited by 1,070
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
Saag, K. G., Koehnke, R., Caldwell, J. R., Brasington, R., Burmeister, L. F., Zimmerman, B., Kohler, J. A., & Furst, D. E. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90131-7 · Cited by 540
van Everdingen, A. A., Jacobs, J. W. G., Siewertsz van Reesema, D. R., & Bijlsma, J. W. J. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-1-200201010-00006 · Cited by 489
Association of Adrenocorticosteroid Therapy and Peptic-Ulcer Disease
Messer, J., Reitman, D., Sacks, H. S., Smith, H., & Chalmers, T. C. (1983) · New England Journal of Medicine · doi:10.1056/nejm198307073090105 · Cited by 422
Laan, R. F. J. M., van Riel, P. L. C. M., van de Putte, L. B. A., van Erning, L. J. T. O., van't Hof, M. A., & Lemmens, J. A. M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-10-199311150-00001 · Cited by 411
Bone loss in response to long-term glucocorticoid therapy
LoCascio, V., Bonucci, E., Imbimbo, B., Ballanti, P., Adami, S., Milani, S., Tartarotti, D., & DellaRocca, C. (1990) · Bone and Mineral · doi:10.1016/0169-6009(91)90139-q · Cited by 384
Walsh, L. J., Wong, C. A., Pringle, M., & Tattersfield, A. E. (1996) · BMJ · doi:10.1136/bmj.313.7053.344 · Cited by 383
Cited by
Long-term side effects of glucocorticoids
Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H., & Foster, C. S. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1140743 · Cited by 869
Depression and anxiety in inflammatory bowel disease: A review of comorbidity and management
Graff, L. A., Walker, J. R., & Bernstein, C. N. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20873 · Cited by 586
The epidemiology of glucocorticoid-associated adverse events
McDonough, A. K., Curtis, J. R., & Saag, K. G. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282f51031 · Cited by 405
A Comprehensive Review of the Adverse Effects of Systemic Corticosteroids
Poetker, D. M., & Reh, D. D. (2010) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2010.04.003 · Cited by 337
Sweeney, J., Patterson, C. C., Menzies-Gow, A., Niven, R. M., Mansur, A. H., Bucknall, C., Chaudhuri, R., Price, D., Brightling, C. E., & Heaney, L. G. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207630 · Cited by 331
Metadata
- Authors
- Fardet, L., Flahault, A., Kettaneh, A., Tiev, K. P., Généreau, T., Tolédano, C., Lebbé, C., & Cabane, J.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-07
- Volume
- 157
- Issue
- 1
- Pages
- 142-148
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W2160936253
- Cited by
- 273
- References
- 48
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Corticosteroid-induced clinical adverse events: frequency, risk factors and patient?s opinion. https://app.cochat.ai/papers/10.1111/j.1365-2133.2007.07950.x
- The paper
- Fardet, L., Flahault, A., Kettaneh, A., Tiev, K. P., Généreau, T., Tolédano, C., Lebbé, C., & Cabane, J. (2007). Corticosteroid-induced clinical adverse events: frequency, risk factors and patient?s opinion. British Journal of Dermatology. https://doi.org/10.1111/j.1365-2133.2007.07950.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.